Literature DB >> 6630285

Acute cardiac toxicity in patients after doxorubicin treatment and the effect of combined tocopherol and nifedipine pretreatment.

R Lenzhofer, U Ganzinger, H Rameis, K Moser.   

Abstract

In two groups of female patients with metastatic breast cancer who had all been pretreated with doxorubicin (350 mg/m2), acute cardiac effects following i.v. doxorubicin bolus injection (60 mg/m2) were recorded on the basis of systolic time intervals (STI). In six patients who received doxorubicin only the ratio between the heart-beat-corrected preejection period and left ventricular ejection time (PEPI:LVETI) as well as the PEP index were found to be significantly increased with a peak at 6 h following drug infusion (P less than 0.001). Another six patients received an identical chemotherapeutic regimen and, in addition, a combination of tocopherol (200 mg i.m. 6 h before treatment) and nifedipine (60 mg p.o. daily from 2 days before doxorubicin infusion). In the pretreatment group, the PEPI:LVETI ration and PEP index remained unchanged during the posttreatment period. Pharmacokinetic analysis of drug concentrations in the plasma revealed a significantly accelerated distribution and elimination of doxorubicin after combined tocopherol and nifedipine pretreatment, although no statistically significant differences could be found in calculated drug levels in the peripheral compartment between both treatment groups. Our results indicate that acute cardiac reactions reflected by changes in STI values can be prevented by combined tocopherol and nifedipine pretreatment.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6630285     DOI: 10.1007/BF00395393

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  24 in total

1.  IGPHARM: interactive graphic package for pharmacokinetic analysis.

Authors:  C Gomeni; R Gomeni
Journal:  Comput Biomed Res       Date:  1978-08

2.  Inhibition by adriamycin of a metmyoglobin reductase from beef heart.

Authors:  D Taylor; P Hochstein
Journal:  Biochem Pharmacol       Date:  1978       Impact factor: 5.858

Review 3.  Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle.

Authors:  A Fleckenstein
Journal:  Annu Rev Pharmacol Toxicol       Date:  1977       Impact factor: 13.820

4.  Interaction of daunomycin and its derivatives with DNA.

Authors:  F Zunino; R Gambetta; A Di Marco; A Zaccara
Journal:  Biochim Biophys Acta       Date:  1972-09-14

5.  Bedside technics for the evaluation of ventricular function in man.

Authors:  A M Weissler; W S Harris; C D Schoenfeld
Journal:  Am J Cardiol       Date:  1969-04       Impact factor: 2.778

6.  Risk factors for doxorubicin-induced congestive heart failure.

Authors:  D D Von Hoff; M W Layard; P Basa; H L Davis; A L Von Hoff; M Rozencweig; F M Muggia
Journal:  Ann Intern Med       Date:  1979-11       Impact factor: 25.391

7.  Sudden death during doxorubicin administration.

Authors:  J E Wortman; V S Lucas; E Schuster; D Thiele; G L Logue
Journal:  Cancer       Date:  1979-11       Impact factor: 6.860

8.  Electrocardiographic changes after adriamycin chemotherapy.

Authors:  M K Ali; A Soto; D Maroongroge; S Bekheit-Saad; A U Buzdar; G R Blumenschein; G N Hortobagyi; C K Tashima; C L Wiseman; C C Shullenberger
Journal:  Cancer       Date:  1979-02       Impact factor: 6.860

9.  Dose-effect and structure-function relationships in doxorubicin cardiomyopathy.

Authors:  M R Bristow; J W Mason; M E Billingham; J R Daniels
Journal:  Am Heart J       Date:  1981-10       Impact factor: 4.749

10.  Cardiomyopathy and other chronic toxic effects induced in rabbits by doxorubicin and possible prevention by coenzyme Q10.

Authors:  N Domae; H Sawada; E Matsuyama; T Konishi; H Uchino
Journal:  Cancer Treat Rep       Date:  1981 Jan-Feb
View more
  3 in total

1.  Nanodiamond delivery circumvents tumor resistance to doxorubicin.

Authors:  Xiao-wei Ma; Yu-liang Zhao; Xing-jie Liang
Journal:  Acta Pharmacol Sin       Date:  2011-05-02       Impact factor: 6.150

Review 2.  Systematic review: generating evidence-based guidelines on the concurrent use of dietary antioxidants and chemotherapy or radiotherapy.

Authors:  Akiko Nakayama; Karen P Alladin; Obianuju Igbokwe; Jeffrey D White
Journal:  Cancer Invest       Date:  2011-12       Impact factor: 2.176

Review 3.  Antioxidants as precision weapons in war against cancer chemotherapy induced toxicity - Exploring the armoury of obscurity.

Authors:  Kanchanlata Singh; Mustansir Bhori; Yasar Arfat Kasu; Ganapathi Bhat; Thankamani Marar
Journal:  Saudi Pharm J       Date:  2017-12-19       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.